drugset / Trial / NCT00434356
A Study of Sunitinib in Combination With Bevacizumab and Paclitaxel in Previously Untreated Patients With Metastatic Breast Cancer (SABRE-B)
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a multicenter, Phase II, randomized, controlled, open label trial designed to provide a preliminary assessment of the safety and efficacy of sunitinib when combined with bevacizumab and paclitaxel in patients who have not previously received chemotherapy for locally recurrent or metastatic breast cancer.
Timeline
- Start
- 2007-03
- Primary completion
- 2008-05
- Completion
- —
Outcome
Outcome not reported
Stopped: “Based on data collected, the combination appeared to be poorly tolearated.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sunitinib | Small molecule | — | Oral |
| Background | Bevacizumab | Monoclonal antibody | — | Intravenous |
| Background | Paclitaxel | Small molecule | — | Intravenous |